Embecta price to free cash flow EMBC

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Oct 23, 2026: 2.3×
4-year median: 12.2×
Against its 4-year history: 13th; percentile: 0 is its lowest day, 100 its highest
4-year range: 0.9× to 95.5×
Peer median: 18.2×

Embecta's price to free cash flow is 2.3× as of Oct 23, 2026.

That is below its 4-year median of 12.2×, lower than on 87% of days in the last 4 years.

Over that time it ranged from 0.9× in Jun 2026 to 95.5× in Jul 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 18.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.3×	0.9×	4.1×
2025	3.9×	3.8×	59.9×
2024	60.5×	23.6×	95.5×
2023	26.3×	3.4×	26.3×
2022	3.7×	3.7×	4.0×

Against its peers

Companies in Medical - Instruments & Supplies nearest Embecta's size, closest first, today.

Company	Price to free cash flow
EMBCEmbecta	2.3×
INFUInfuSystem	12.1×
TCMDTactile Systems Technology	20.0×
MDXGMimedx	n/m
UTMDUtah Medical Products	20.6×
MOVMovado	9.8×
PDEXPro DEX	29.5×
IRMDIradimed	43.7×
STAAStaar Surgical	n/m
BVSBioventus	13.3×
CDRECadre	16.4×
Peer median	18.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Embecta

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.